



Supplemental Figure 1. A) Gating strategies for the phenotypic analysis of infiltrating immune cells in the kidney. Lymphocyte gating is based on the forward scatter vs side scatter, which is further gated on CD4+ or CD8+ T cells or B-cells or DC/M ϕ . These populations were analyzed further based on IL-17 or Orai1 expression as described in text. B) Expression of Orai1 and Orai1+/IL17+ cells in CD8, B cells, NK cells and macrophages.




Supplemental Figure 2. Orai2 and Orai3 expression in kidney lymphocytes following renal I/R injury. A) Representative histogram of Orai2+ lymphocytes (left panel) and percent CD4+/Orai2+ cells in kidney 2 days following sham or I/R injury. B) Representative histogram of Orai3+ lymphocytes (left panel) and percent CD4+/Orai3+ cells in kidney 2 days following sham or I/R injury. Data are mean \pm SE from a minimum of 3 independent rats per group; no statistical differences were observed between sham and I/R.




Supplemental Figure 3. Characterization of the cells used for in vitro stimulation following AKI priming. A) Representative FACS analysis of ROR γ T staining in CD4⁺ cells isolated 7 days following sham or I/R surgery. B) Renal injury primes IL17 mRNA response in kidney derived CD4⁺ cells. Renal CD4 cells were isolated from kidney 7 days following sham (open bar) or I/R surgery (black bar). Cells were incubated for 12-14 hours in media containing either 140 or 170 mM Na⁺ with or without Ang II (10^{-7} M) as shown. To control for supplementation of NaCl to the media, some samples were stimulated with equimolar mannitol (60 mM) or choline chloride (30 mM) as shown. IL17 mRNA is expressed as $2^{-\Delta\Delta Ct}$ and is mean \pm SE from a minimum of 3 independent rats per group; * indicates $P < 0.05$ vs control (i.e., 140 mM Na⁺, no added Ang II), by one-ANOVA and Tukey's post-hoc test. Note the response of AKI primed cells with Ang II and added Na⁺ indicated by the arrow represent the control condition used in Figure 2C. C) Representative contour plots indicating the co-expression of IL17 with ROR γ T (RoRyc) in CD4⁺ cells from post-AKI rat kidney under control conditions and following stimulation with Ang II and elevated Na. D) Representative FACS analysis of CD4⁺ cells from post-IR rat kidney illustrating central memory T cells (CD44⁺CD62L⁻) before and after in vitro stimulation.

(A)



(B)



Supplemental Figure 4. A) Schematic outline of timeline to investigate the role of SOCE in progression of CKD following acute I/R injury. B) Renal Kim-1 expression measured in sham, I/R vehicle and YM 58483 is shown.

Supplemental Table 1a. Antibodies utilized for flow cytometry for rat studies

| Name | Catalog | Clone | Source |
|------------------------------------|------------|----------|---------------|
| Mouse anti-rat CD4 PE-Cy5 | 554839 | OX-35 | BD Pharmingen |
| Mouse anti-rat CD8 Alexa fluor 647 | 561611 | OX-8 | BD Pharmingen |
| IL-17A monoclonal antibody FITC | 11-7177-80 | Ebio17b7 | ebiosciences |
| Mouse anti-rat IFN- γ FITC | 559498 | DB-1 | BD Pharmingen |
| PE mouse anti-rat IL-4 | 555082 | OX-81 | BD Pharmingen |
| FITC Mouse Anti-Rat RT1B | 554928 | OX-6 | BD Pharmingen |
| FITC Mouse Anti-Rat CD11b/c | 554862 | OX-42 | BD Pharmingen |
| Anti-Orai-1 | ACC-062 | Peptide | Alomone Lab |
| Anti-rat CD44 APC | FAB6577A | 740017 | RnD Biosystem |
| Anti-Orai-2 | ACC-061 | Peptide | Alomone Lab |
| Anti-Orai-3 | ACC-065 | Peptide | Alomone Lab |
| Anti-RoRyc | 562607 | Q31-378 | BD Pharmingen |

Supplemental Table 1b. Antibodies utilized for flow cytometry for human studies

| Name | Catalog | Clone | Source |
|----------------|---------|---------|--------------|
| Anti-IL-17 PE | 512306 | BL168 | Biolegend |
| Anti-CD4 PerCp | 317432 | OKT4 | Biolegend |
| FITC orai-1 | ACC-060 | Peptide | Alomone Labs |

Supplemental Table 2: Percent of Orai1 expression in different leukocyte populations in kidney following sham and I/R injury.

| | %Orai1+ cells | |
|---------|---------------|------------|
| | Sham | I/R |
| CD4 | 27.1±9.8 | 77.9±15.3* |
| CD8 | 0.85±0.01 | 0.59±0.02 |
| B cells | 0.98±0.48 | 1.47±0.35 |
| CD11b/c | 3.2±0.7 | 5.5±0.65 |

* indicates $P < 0.05$ I/R vs sham by Student's t-test.